Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
May 25, 2026 (Issue: 1755)
The FDA has approved orforglipron (Foundayo – Lilly), an
oral small-molecule, nonpeptide glucagon-like peptide-1
(GLP-1) receptor agonist, to reduce excess body weight and
maintain weight reduction long term in adults with obesity, or
with...more
- Oral semaglutide (Wegovy) for weight loss. Med Lett Drugs Ther 2026; 68:17.
- SE Kanoski et al. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016; 310:R885. doi:10.1152/ajpregu.00520.2015
- X Ma et al. Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight. Diabetes Obes Metab 2026 April 17 (epub). doi:10.1111/dom.70783
- S Wharton et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med 2025; 393:1796. doi:10.1056/nejmoa2511774
- DB Horn et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet 2025; 406:2927. doi:10.1016/s0140-6736(25)02165-8
- In brief: GI effects of GLP-1 receptor agonists. Med Lett Drugs Ther 2023; 65:191.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly.May 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
Article code: 1755a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
